November 24th 2024
Patients experienced similar safety and efficacy if they received first-line or later-line treatment for unresectable hepatocellular carcinoma (u-HCC).
Larry D. Anderson Jr, MD, PhD, associate professor, Harold C. Simmons Comprehensive Cancer Center, discusses updated findings of the phase II KarMMa trial assessing ide-cel chimeric antigen receptor (CAR) T-cell therapy for treatment of adult patients with relapsed or refractory multiple myeloma after 4 or more prior lines of therapy.
Watch
Community-Based Initiative Doubles Accrual Rate of Black Participants in Cancer Trials
June 9th 2021An initiative launched with the intent to deliver equitable cancer care improved the enrollment rates of Black participants in cancer clinical trials by focusing on community outreach and engagement.
Read More
Softer Alignment of Medicare ACOs May Still Lead to Higher Prices for Office Visits
June 7th 2021The researchers created a model that simulated what would happen when health systems and providers began working together in Medicare accountable care organizations (ACOs) in arrangements that did not extend to outright mergers or acquisitions.
Read More
Rajat Bannerji, MD, PhD, Chief, Section of Hematologic Malignancies at Rutgers Cancer Institute of New Jersey/RWJBarnabas Health, speaks on the efficacy and safety findings of the CAPTIVATE study examining the fixed-duration regimen of ibutinib and venetoclax combination therapy in CLL.
Watch
Antoine Italiano, MD, PhD, head of Early Phase Trials and Sarcoma Units at Institut Bergonié, Bordeaux, France, addresses findings of an extended follow-up of larotrectinib in patients with TRK fusion cancer that indicated prolonged progression-free survival in those undergoing the NTRK inhibitor.
Watch
Contributor: It’s Time for Medicare to Cover Oral Alternative Therapies for Iron Deficiency Anemia
June 6th 2021The founder of the Renal Support Network discusses why patients with chronic kidney disease want Congress to change Medicare policy to allow payment for oral treatments for anemia caused by iron deficiency.
Read More
Kirk Shepard, MD, chief medical officer, senior vice president, and head of Global Medical Affairs, Eisai, discusses findings of a study showcasing similar health-related quality of life (HRQOL) scores between lenvatinib/pembrolizumab vs chemotherapy in patients with advanced endometrial carcinoma.
Watch
Dr Christopher Arendt on OPTIC Findings for Dose Optimization of Ponatinib in Patients With CP-CML
June 5th 2021Christopher Arendt, PhD, head, Oncology Therapeutic Area Unit, Takeda, speaks on efficacy and safety findings of the OPTIC study examining dose optimization of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) resistant to second-generation tyrosine kinase inhibitor therapy.
Watch
Sex and Age Differences Found in Virus-Related ED Visits, Hospitalization in COPD
June 5th 2021Variances between sex and age were found among patients with chronic obstructive pulmonary disease (COPD) with a viral infection who visited the emergency department (ED) visit or were hospitalized, highlighting the role that these factors play.
Read More
Robert Iannone, MD, MSCE, executive vice president of research and development for Jazz Pharmaceuticals, addresses findings of an abstract presented at ASCO 2021 which showed preliminary efficacy of lurbinectedin in combination with irinotecan in patients with advanced endometrial carcinoma.
Watch
Dr Peter Dicpinigaitis Highlights Key Presentations at the American Cough Conference
June 4th 2021The 2-day meeting of the American Cough Conference will cover new developments in the treatment of cough, as well as insights into the mechanisms and management of cough, said Peter Dicpinigaitis, MD, chair of the American Cough Conference.
Watch
Redefining Value Assessment to Better Engage Employers, Optimize Health Care Decision-Making
June 3rd 2021Stakeholders discuss barriers and solutions to employer engagement on value assessment, which includes redefining goals to that of the employer and patient, and moving beyond the scope of cost and clinical outcomes.
Read More
Tracking Health Indicators After COVID-19 Requires Real-Time Capabilities
June 3rd 2021In this white paper from Humana, the authors discuss how the aftermath of COVID-19 will require the frequent use of screeners and tools to assess changes in health status, including health-related quality of life and social health. Taking into account the results that matter most to patients will be key to improving health outcomes.
Read More
Contributor: A Renewed Call to Arms to Defeat HIV/AIDS on Its 40th Anniversary
June 2nd 2021On the eve of the 40th anniversary of the CDC’s first report on what would become known as HIV/AIDS, Perry N. Halkitis, PhD, MS, MPH, sends out an urgent call to continue this fight and rededicate resources to finding a cure.
Read More
Contributor: Maintaining the Doctor-Patient Connection During the COVID-19 Pandemic
May 29th 2021Christine Ko, MD, professor of dermatology and pathology at Yale University, reflects on her use of telehealth and how it allowed her to establish and maintain emotional connections with her patients, all at high risk of skin cancer.
Read More
Addressing the Demand for Mental Health Services During the COVID-19 Pandemic
May 25th 2021On this episode of Managed Care Cast, we speak with Gregory Harris, MD, MPH, DFAPA, senior medical director for behavioral health at Blue Cross Blue Shield of Massachusetts, about the challenges of meeting the demand for mental health service during the COVID-19 pandemic.
Listen
Higher Inpatient Risk of COVID-19–Related Mortality Associated With Parkinson Disease
May 24th 2021A higher risk of COVID-19–related mortality was found among hospitalized patients with Parkinson disease (PD) than in the general population. Overall inpatient mortality of those with PD was also significantly higher in 2020 than in the year prior.
Read More